Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762643 | 0.91 | TSHR (0.40) | ULK1HCRTR1TBK1HCRTR2 | |
| SCHEMBL6004400 | 0.88 | ULK1 (0.39) | ULK1HCRTR1IKBKETBK1SCN9A | |
| SCHEMBL4877473 | 0.86 | HDAC3 (0.40) | ULK1HCRTR1HCRTR2 | |
| SCHEMBL6004201 | 0.81 | HDAC3 (0.38) | ULK1HCRTR1HCRTR2 | |
| SCHEMBL6002824 | 0.71 | TGFBR1 (0.45) | ULK1ALKSCN9A | |
| SCHEMBL6004445 | 0.71 | TRPM8 (0.48) | — | |
| SCHEMBL4761319 | 0.67 | DYRK1A (0.38) | ULK1 | |
| SCHEMBL6002744 | 0.67 | TRPM8 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL4828522 | 0.66 | CHEK1 (0.40) | ALKSCN9A | |
| SCHEMBL4868017 | 0.66 | ACVR1 (0.42) | ULK1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ULK1 290/4885ALK 804/4885HCRTR1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.